Clinical Trial Update: ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ECT with pembrolizumab for unresectable melanoma with superficial or superficial and visceral metastases has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: European Institute of Oncology | Conditions: Malignant Melanoma | Phase 2 | Status: WITHDRAWN